Immune Cells Regulate Matrix Metalloproteinases to Reshape the Tumor Microenvironment to Affect the Invasion, Migration, and Metastasis of Pancreatic Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2023 Jan 11

PMID 36628243

Authors

Chunqiu Wang

Zhen Deng

Longjun Zang

Yufeng Shu

Suifang He

Xin Wu

Affiliations

Soon will be listed here.

Abstract

This study aimed to identify author, country, institutional, and journal collaborations and assess their impact, along with knowledge base, as well as identify existing trends, and uncover emerging topics related to matrix metalloproteinase and pancreatic-cancer research. A total of 1474 Articles and reviews were obtained from the Web of Science Core Collection and analyzed by Citespace and Vosviewer. CANCER RESEARCH, CLINICAL CANCER RESEARCH, and FRONTIERS IN IMMUNOLOGY are the most influential journals. The three main aspects of research in matrix metalloproteinases-pancreatic cancer-related fields included the pathogenesis mechanism of pancreatic cancer, how matrix metalloproteinases affect the metastasis of pancreatic cancer, and what role matrix metalloproteinases play in pancreatic cancer treatment. Tumor microenvironment, pancreatic stellate cells, drug resistance, and immune cells have recently emerged as research hot spots. In the future, exploring how immune cells affect matrix metalloproteinases and reshape the tumor microenvironment may be the key to curing pancreatic cancer. This study thus offers a comprehensive overview of the matrix metalloproteinases-pancreatic cancer-related field using bibliometrics and visual methods, providing a valuable reference for researchers interested in matrix metalloproteinases-pancreatic cancer.

Citing Articles

NCKAP1 as a prognostic and immunological biomarker: pan-cancer analysis and validation in renal clear cell carcinoma.

Liang X, Hong A, Shen R, Zhu M, Tian W Am J Transl Res. 2024; 16(8):4083-4100.

PMID: 39262720 PMC: 11384366. DOI: 10.62347/UKQB2042.

Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study.

Cheng K, Li W, Wu H, Li C Front Mol Biosci. 2023; 10:1302016.

PMID: 38111465 PMC: 10725992. DOI: 10.3389/fmolb.2023.1302016.

References

Jaster R . Molecular regulation of pancreatic stellate cell function. Mol Cancer. 2004; 3:26. PMC: 524499. DOI: 10.1186/1476-4598-3-26. View

Bardeesy N, DePinho R . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12):897-909. DOI: 10.1038/nrc949. View

Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H . Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol Cancer. 2005; 4:37. PMC: 1266395. DOI: 10.1186/1476-4598-4-37. View

Wu Z, Zhang X, Chen D, Li Z, Wu X, Wang J . N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma. Front Immunol. 2022; 12:806189. PMC: 8790065. DOI: 10.3389/fimmu.2021.806189. View

Peng J, Yang Q, Shi K, Xiao Y, Wei X, Qian Z . Intratumoral fate of functional nanoparticles in response to microenvironment factor: Implications on cancer diagnosis and therapy. Adv Drug Deliv Rev. 2019; 143:37-67. DOI: 10.1016/j.addr.2019.06.007. View

Chen C, Dubin R, Kim M . Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014). Expert Opin Biol Ther. 2014; 14(9):1295-317. DOI: 10.1517/14712598.2014.920813. View

Wu X, Zhang X, Feng W, Feng H, Ding Z, Zhao Q . A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects. ACS Appl Mater Interfaces. 2021; 13(24):27920-27933. DOI: 10.1021/acsami.1c06059. View

Wu K, Liu Y, Liu L, Peng Y, Pang H, Sun X . Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study. Front Oncol. 2022; 12:810774. PMC: 9063039. DOI: 10.3389/fonc.2022.810774. View

Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S . Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021; 6(1):153. PMC: 8062524. DOI: 10.1038/s41392-021-00544-0. View

10.

Fayyad A, Lapp S, Risha E, Pfankuche V, Rohn K, Barthel Y . Matrix metalloproteinases expression in spontaneous canine histiocytic sarcomas and its xenograft model. Vet Immunol Immunopathol. 2018; 198:54-64. DOI: 10.1016/j.vetimm.2018.03.002. View

11.

Wu X, Li S, Chen D, Zheng G, Zhang Z, Li Z . An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia. Am J Transl Res. 2022; 14(7):4898-4917. PMC: 9360836. View

12.

Qian M, Wang S, Guo X, Wang J, Zhang Z, Qiu W . Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways. Oncogene. 2019; 39(2):428-442. DOI: 10.1038/s41388-019-0996-y. View

13.

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

14.

Shen J, Shen H, Ke L, Chen J, Dang X, Liu B . Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol. 2022; 13:815575. PMC: 8841606. DOI: 10.3389/fimmu.2022.815575. View

15.

Sun H, Bai W, Li X, Huang H, Cui X, Cheung T . Schizophrenia and Inflammation Research: A Bibliometric Analysis. Front Immunol. 2022; 13:907851. PMC: 9219580. DOI: 10.3389/fimmu.2022.907851. View

16.

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

17.

Bapat A, Hostetter G, Von Hoff D, Han H . Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer. 2011; 11(10):695-707. DOI: 10.1038/nrc3131. View

18.

Bloomston M, Zervos E, Rosemurgy 2nd A . Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002; 9(7):668-74. DOI: 10.1007/BF02574483. View

19.

Overall C, Kleifeld O . Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3):227-39. DOI: 10.1038/nrc1821. View

20.

Hofmann U, Eggert A, Blass K, Brocker E, Becker J . Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res. 2003; 63(23):8221-5. View